Experience:
No experience
Employment Type:
Intern/Co-op
Posted:
2/21/2019
Job Category:
Education
Intern: LC-MS targeted lipidomic assay development
(This job is no longer available)
Biogen Idec | Cambridge, MA
loading
loading
School
Major
Grad Date
 
 

Not sure what types of jobs you are interested in?


Explore Jobs
Based on Your Education

Follow This Company
Share

Job Description

Job Description

This 3-month intern position will be focused on assisting LC-MS assay development with key responsibilities:

* Perform bench work on biological samples preparation for LC-MS lipid analysis;
* Operate Waters and Agilent chromatographic instrument
* Data acquisition on ABSciex Triple Quad and Bruker FT ICR mass spectrometers;
* Optimize and validate quantitative targeted LC-MS assays.

Qualifications

* Experienced on chromatography and mass spectrometry
* Experienced on chemistry/biology lab bench work
* Meticulous, organized and communicate effectively

To participate in the Biogen Intern or Co-op Program, students must meet the following eligibility criteria:

* Legal authorization to work in the U.S.
* Enrollment in a full-time undergraduate or graduate program, returning to the academic program following Biogen Intern or Co-op assignment
* Minimum grade point average of 3.2 preferred
* At least 18 years of age prior to the scheduled start date
* Completed at least one year of undergraduate studies

Education

* Graduate or Undergraduate students
* Must be enrolled in a Degree program in analytical chemistry /chemistry/ biochemistry/ biology

About Biogen Idec

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)